Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Public ClinicalTrials.gov record NCT01005329. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies the side effects of giving intensity-modulated radiation therapy together with cisplatin and bevacizumab followed by carboplatin and cisplatin and to see how well they work in treating patients who have undergone surgery for high-risk endometrial cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving intensity-modulated radiation therapy together with chemotherapy and bevacizumab after surgery may kill any tumor cells that remain after surgery.
Study identification
- NCT ID
- NCT01005329
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Stage IA Uterine Corpus Cancer AJCC v7
- Stage IB Uterine Corpus Cancer AJCC v7
- Stage II Uterine Corpus Cancer AJCC v7
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Stage IVA Uterine Corpus Cancer AJCC v7
- Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
- Bevacizumab Biological
- Carboplatin Drug
- Cisplatin Drug
- Intensity-Modulated Radiation Therapy Radiation
- Paclitaxel Drug
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2009
- Primary completion
- Jun 29, 2012
- Completion
- Sep 21, 2013
- Last update posted
- Mar 14, 2018
2009 – 2013
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | 94704 | — |
| John Muir Medical Center-Walnut Creek | Walnut Creek | California | 94598 | — |
| Penrose-Saint Francis Healthcare | Colorado Springs | Colorado | 80907 | — |
| Poudre Valley Hospital | Fort Collins | Colorado | 80524 | — |
| Christiana Care Health System-Christiana Hospital | Newark | Delaware | 19718 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Integrated Community Oncology Network-Southside Cancer Center | Jacksonville | Florida | 32207 | — |
| University of Florida Health Science Center - Jacksonville | Jacksonville | Florida | 32209 | — |
| Baptist Medical Center South | Jacksonville | Florida | 32258 | — |
| Integrated Community Oncology Network-Florida Cancer Center Beaches | Jacksonville Beach | Florida | 32250 | — |
| 21st Century Oncology-Orange Park | Orange Park | Florida | 32073 | — |
| 21st Century Oncology-Palatka | Palatka | Florida | 32177 | — |
| Bay Medical Center | Panama City | Florida | 32401 | — |
| Integrated Community Oncology Network-Flager Cancer Center | Saint Augustine | Florida | 32086 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| John H Stroger Jr Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Saint Vincent Anderson Regional Hospital/Cancer Center | Anderson | Indiana | 46016 | — |
| Saint Vincent Hospital and Health Care Center | Indianapolis | Indiana | 46260 | — |
| Kansas City NCI Community Oncology Research Program | Prairie Village | Kansas | 66208 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Central Maryland Radiation Oncology in Howard County | Columbia | Maryland | 21044 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Elliot Hospital | Manchester | New Hampshire | 03103 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Summa Akron City Hospital/Cooper Cancer Center | Akron | Ohio | 44304 | — |
| Summa Barberton Hospital | Barberton | Ohio | 44203 | — |
| Flower Hospital | Sylvania | Ohio | 43560 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Paoli Memorial Hospital | Paoli | Pennsylvania | 19301 | — |
| Radiation Therapy Oncology Group | Philadelphia | Pennsylvania | 19103 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
| Wheeling Hospital/Schiffler Cancer Center | Wheeling | West Virginia | 26003 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
Recently updated Endometrial Adenocarcinoma trials
Other public records listing Endometrial Adenocarcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07705035: DBC-664 in Adult Patients With Solid Tumors Recruiting
- NCT07675967: Clonal Hematopoiesis Chemotherapy and Radiation Effects Study Recruiting
- NCT02208375: mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting
- NCT05548296: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma Recruiting
- NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Active, not recruiting
- NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01005329, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01005329 live on ClinicalTrials.gov.